Abstract: The invention relates to methods and reagents for the identification of the origin of a carcinoma of unknown primary origin (CUP) based on the determination of the methylation profile in the genome of the CUP. The invention relates as well to methods for selecting a suitable therapy for a patient suffering a CUP as well as to methods for personalized medicine of patient suffering a CUP based on the use of a treatment which is adequate for the primary tumor from which the CUP is derived. The invention also relates to kits comprising reagents adequate for performing the above methods as well as to computer systems and programs which can be used for implementing the methods of the invention.
Type:
Application
Filed:
May 24, 2012
Publication date:
January 21, 2016
Applicants:
FUNDACIÓ INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL), FUNDACIÓ INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS
Abstract: The present invention is directed to pioglitazone, or a pharmaceutically acceptable salt thereof, as well as a pharmaceutical composition comprising pioglitazone, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, for use in the treatment and/or prevention of an adrenoleukodystrophy.
Type:
Grant
Filed:
March 13, 2013
Date of Patent:
October 21, 2014
Assignees:
Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL), Fundació Institució Catalana de Recerca I Estudis Avançats (ICREA), Fondation ELA